

OLB24

2-hour Oral Session

Late breaker session: Other

Multicentre evaluation of the FilmArray meningitis/encephalitis panel

Marijke Raymaekers^{*1}, Reinoud Cartuyvels¹, Claeys Vicky², Derdin Sanne¹, Germis Cindy³, Jos Van Acker³, Elke Vanlaere³, Marijke Reynders⁴, Floré Katelijne²

¹Jessa Hospital, Clinical Biology, Laboratory for Molecular Diagnostics, Hasselt, Belgium

²Az Sint Lucas, Laboratory Medicine, Medical Microbiology, Brugge, Belgium

³Az Sint-Lucas, Laboratory of Clinical Microbiology, Gent, Belgium

⁴Az Sint-Jan Brugge-Oostende Av, Laboratory Medicine, Brugge, Belgium

Background:

Recently, the FilmArray meningitis/encephalitis (ME) panel was launched on the FilmArray® platform (Biofire, Salt Lake City, US), an assay for the simultaneous detection of 14 pathogens.

The aim of this multicentre study was to verify the limit of detection (LOD) and the accuracy of all included pathogens as described in the package insert. To guarantee equal results, an inter-laboratory-evaluation was organised.

Material/methods:

All experiments were carried out according to the manufacturer's instructions, using the ME panel v1.4 and protocol CSF v3.0.

The LOD experiments were performed by analysing each pathogen at a concentration of 2- 3 times the LOD. Bacterial NCTC/ATCC strains were cultured, diluted and quantified by colony counting of culture media. Because of the lack of availability of well-defined strains for *Escherichia coli* K1 and *Cryptococcus neoformans/gattii*, LOD experiments were not performed for these pathogens. For viruses, dilutions of QCMD samples with known concentration were analysed. Each dilution was analysed once. In case of a negative result the sample was re-analysed in duplicate. If the LOD could not be confirmed, a dilution with a higher concentration was made and analysed in the same way as described.

For the accuracy experiment, 17 clinical samples with none of the suspected pathogens present were analysed. A total of 42 samples suspicious for ME were also analysed. The clinical presentation was combined with other laboratory test results. Discordant results were confirmed with an in-house real-time PCR as referee.

The inter-laboratory evaluation was performed by analysing a physiologic salt solution and a 1:5 dilution of a pool of NATrol™ ME Controls (Zeptomatrix, Buffalo, US) on all sites at 3 different time points, to assess transport and storage conditions.

Results:

The LOD could be confirmed for all pathogens, except for some strains of *H. influenzae*. Figure 1 gives an overview of the LOD as claimed by the manufacturer, compared to our findings.

In 2 of the 17 suspected negative samples, a viral pathogen (Enterovirus and Human herpes virus 6 (HHV6)) was found. The Enterovirus result could not be confirmed by 2 in-house PCRs, nor by GeneXpert (Cepheid).

Out of 42 positive samples, 4 samples reported as false negative. In 3 of the QCMD samples, a positive result for HHV6 was obtained which could not be confirmed by an in-house PCR.

All sites reproduced the same results in the inter-laboratory evaluation, indicating that samples can be kept at room temperature and at 2-8°C for at least 1 and 7 days respectively.

Conclusions:

The FilmArray ME panel seems a promising and useful assay in the diagnosis of central nervous infections. LOD's as claimed by the manufacturer were confirmed except for some strains of *H. influenzae*. Discordant results obtained in the accuracy experiment need further investigation.

| Pathogen | Sample (concentration/ml) | LOD (concentration/ml) | Result Filmarray |
|---------------------------------|---|---|--|
| <i>Haemophilus influenzae</i> | NTC 8468 (1600 CFU) | 1000 CFU | Negative (3x) |
| | NTC 8468 (2800 CFU) | | Negative (3x) |
| | NTC 8468 (3800 CFU) | | Negative (3x) |
| | NTC 8468 (4100 CFU) | | Positive (1x) |
| | NTC 8468 (8000 CFU) | | Positive (1x) |
| | ATCC 10211 (2410 CFU) | | Positive (1x) |
| <i>Listeria monocytogenes</i> | ATCC 13932 (1560 CFU) | 1000 CFU | Positive (1x) |
| <i>Neisseria meningitidis</i> | ATCC 13090 (1200 CFU) | 100 CFU | Positive (1x) |
| | ATCC 1309 (480 CFU) | | Positive (1x) |
| <i>Streptococcus agalactiae</i> | ATCC 12386 (1120 CFU) | 1000 CFU | Negative (3x) |
| | ATCC 12386 (2300 CFU) | | Negative (2x) and positive (1x) |
| | ATCC 12386 (3500 CFU) | | Positive (1x) |
| | ATCC 12386 (5600 CFU) | | Positive (1x) |
| <i>Streptococcus pneumoniae</i> | ATCC 49619 (400 CFU) | 100 CFU | Positive (1x) |
| Cytomegalovirus | QCMD2014-07 (8318 copies) | 4300 copies | Positive (also positive for HHV6, not confirmed with in-house PCR) |
| Enterovirus Coxsackie A9 | QCMD2013-03 (10 TCID ₅₀) | 5 TCID ₅₀ | Positive (1x) |
| Enterovirus type A16 | QCMD2013-07 (10 TCID ₅₀) | A16: not mentioned, A17: 5 TCID ₅₀ | Positive (1x) |
| Herpes simplex virus 1 | QCMD2014-01 (5408 copies) | 1510 copies | Positive (1x) |
| Herpes simplex virus 2 | QCMD2014-08 (5023 copies) | 1290 copies | Positive (1x) |
| Human herpes virus 6 | QCMD 2015 C2-04 (11000 copies) | 10000 copies | Positive (1x) |
| Parechovirus | QCMD EV2010-04 (2240 TCID ₅₀) | 500 TCID ₅₀ | Positive (1x) |
| Varicella zoster virus | QCMD2014-09 (4140 copies) | 1660 copies | Positive (1x) |